- HEXPOL TPE invests 57 Million SEK in Åmål, Sweden.
- The investment will expand production capacity and ensure product safety.
- A new production hall for medical TPE materials will be completed by autumn 2022.
- The facility will feature advanced technology including a twin-screw compounding line.
Investment and Expansion
HEXPOL TPE has announced a 57 Million SEK investment (approx. €6 mio) at their facility in Åmål, Sweden. This investment aims to support increasing demand and evolving market requirements by expanding production capacity and ensuring product safety standards across their materials portfolio.
Focus on Medical Production
The company specializes in Thermoplastic Elastomer (TPE) materials for sensitive and regulated applications, including medical devices, toys, consumer products, automotive, and food contact. A new production hall is being constructed specifically for medical production, featuring strict cleanliness, traceability, and reproducibility controls. The facility is designed to minimize contamination risks and will house a new twin-screw compounding line with gravimetric feeders and advanced monitoring systems.
Timeline and Technology
Construction of the new production hall began in September 2021, with the aim to complete the project by autumn 2022. The new facility will enhance internal logistics and increase automation and robotics, laying the foundation for future development.
Historical Context
HEXPOL TPE produced their first medical compounds in the 1990s and launched the Mediprene range of TPEs for medical applications in 2004. Continuous investment in technology, people, and processes led to the company becoming the first TPE compounder in Europe to gain ISO 13485 accreditation in 2007.
